While some authors reported that ITPA rs1127354 is a useful predictor of the development of severe anemia in telaprevir-based triple therapy patients [34, 36], Aghemo et al. reported that an ITPA polymorphism was not associated with early anemia or therapy modification [35]. The gene discussed is ITPA; the disease is anemia.